Pancreatic Cancer Research

ResearcherBeckman Research InstituteActive in the last 2 years

Meilin Xue

Matched on ORCID iD 0009-0000-8927-3678; OpenAlex author ID A5112880506. Sources: OpenAlex.

Their work

Papers
8
Trials
0
Grants
0
Labs led
0
Collaborators
39
Papers, trials and grants by year

2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 3 papers · 2024: 1 paper · 2025: 1 paper

Papers 8

  1. TFAP2A enhances tumor stemness and promotes metastasis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.isci.2025.113060↗
  2. BHLHE40 Inhibits Ferroptosis in Pancreatic Cancer Cells via Upregulating SREBF1. Co-author DOI 10.1002/advs.202306298↗
  3. Identification of a novel immune checkpoint molecule V-set immunoglobulin domain-containing 4 that leads to impaired immunity infiltration in pancreatic ductal… Co-author DOI 10.1007/s00262-023-03438-y↗
  4. Schwann cells regulate tumor cells and cancer-associated fibroblasts in the pancreatic ductal adenocarcinoma microenvironment. Co-author DOI 10.1038/s41467-023-40314-w↗
  5. LIPH contributes to glycolytic phenotype in pancreatic ductal adenocarcinoma by activating LPA/LPAR axis and maintaining ALDOA stability. Co-author DOI 10.1186/s12967-023-04702-6↗
  6. Cystatin B increases autophagic flux by sustaining proteolytic activity of cathepsin B and fuels glycolysis in pancreatic cancer: CSTB orchestrates autophagy a… Co-author DOI 10.1002/ctm2.1126↗
  7. Tumor-associated macrophages promote pancreatic ductal adenocarcinoma progression by inducing epithelial-to-mesenchymal transition. Co-author DOI 10.18632/aging.202264↗
  8. Serum tRNA-derived small RNAs as potential novel diagnostic biomarkers for Pancreatic Ductal Adenocarcinoma Co-author DOI 10.21203/rs.3.rs-63978/v1↗

Closest collaborators

The 25 strongest of 39 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Lingxi Jiang · 8 shared papers, 2020–2025 · strength 1.20
  2. Youwei Zhu · 6 shared papers, 2021–2024 · strength 0.88
  3. Cheng Xiong · 5 shared papers, 2021–2023 · strength 0.73
  4. Hao Chen · 4 shared papers, 2021–2023 · strength 0.60
  5. Lijie Han · 4 shared papers, 2022–2024 · strength 0.58
  6. Baiyong Shen · 4 shared papers, 2020–2024 · strength 0.56
  7. Yizhi Cao · 3 shared papers, 2023–2025 · strength 0.50
  8. Yongsheng Jiang · 3 shared papers, 2021–2023 · strength 0.43
  9. Chenghong Peng · 3 shared papers, 2020–2024 · strength 0.40
  10. Xiaomei Tang · 2 shared papers, 2024–2025 · strength 0.37
  11. Jiaxin Luo · 2 shared papers, 2024–2025 · strength 0.37
  12. Baiyong Shen · 2 shared papers, 2022–2023 · strength 0.29
  13. Hao Chen · 2 shared papers, 2023–2024 · strength 0.29
  14. Xiaxing Deng · 2 shared papers, 2020–2023 · strength 0.24
  15. Kexian Li · 1 shared paper, 2025 · strength 0.21
  16. Dongjie Chen · 1 shared paper, 2025 · strength 0.21
  17. Ting Wang · 1 shared paper, 2023 · strength 0.16
  18. Zhichong Wu · 1 shared paper, 2023 · strength 0.16
  19. Xiaozhu Lin · 1 shared paper, 2023 · strength 0.16
  20. Lijie Han · 1 shared paper, 2023 · strength 0.16
  21. Jiän Zhang · 1 shared paper, 2023 · strength 0.16
  22. Minwei Yang · 1 shared paper, 2023 · strength 0.16
  23. Jiejie Qin · 1 shared paper, 2024 · strength 0.15
  24. Shuyu Zhai · 1 shared paper, 2024 · strength 0.15
  25. Yihao Liu · 1 shared paper, 2024 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.